logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.
  • Medications for Osteitis Deformans

    FiltersReset Filters
    8 results
    • alendronate

      (Alendronate sodium tablet)
      Marlex Pharmaceuticals Inc
      Usage: Alendronate sodium is indicated for treating osteoporosis in postmenopausal women, increasing bone mass in men with osteoporosis, preventing postmenopausal osteoporosis, treating glucocorticoid-induced osteoporosis, and managing Paget's disease of bone in symptomatic patients or those at risk for complications. Reinforcement of therapy need is recommended periodically.
    • calcitonin salmon

      (CALCITONIN SALMON)
      Cipla USA Inc.
      Usage: Calcitonin salmon injection is indicated for treating symptomatic Paget's disease of bone, hypercalcemic emergencies, and postmenopausal osteoporosis in women over five years postmenopause. It is recommended for patients unable to use alternative treatments, and the need for continued therapy should be periodically reassessed due to potential malignancy risk.
    • miacalcin

      (calcitonin salmon)
      Mylan Institutional LLC
      Usage: Miacalcin injection is indicated for treating symptomatic Paget’s disease of bone, hypercalcemic emergencies, and postmenopausal osteoporosis in patients unsuitable for alternative therapies. Its use should be periodically re-evaluated due to potential malignancy associations. No fracture reduction efficacy has been demonstrated for osteoporosis treatment.
    • miacalcin

      (calcitonin salmon)
      Mylan Institutional LLC
      Usage: Miacalcin injection is indicated for treating symptomatic Paget’s disease of bone, hypercalcemic emergencies, and postmenopausal osteoporosis in patients who cannot tolerate or are unsuitable for alternative therapies. Its long-term use requires periodic re-evaluation due to potential malignancy risks.
    • risedronate sodium

      (risedronate sodium)
      Sun Pharmaceutical Industries, Inc.
      Usage: Risedronate sodium tablets are indicated for treating and preventing postmenopausal osteoporosis, increasing bone mass in men with osteoporosis, preventing glucocorticoid-induced osteoporosis, and treating Paget's disease of bone. Periodic re-evaluation of treatment necessity is recommended for all patients.
    • risedronate sodium

      (Risedronate Sodium)
      Apotex Corp.
      Usage: Risedronate sodium tablets are indicated for treating and preventing postmenopausal osteoporosis, increasing bone mass in men with osteoporosis, preventing glucocorticoid-induced osteoporosis, and treating Paget's disease of bone. The safety and effectiveness are based on three years of clinical data. Regular re-evaluation of therapy needs is advised.
    • risedronate sodium

      (Risedronate Sodium)
      Aurobindo Pharma Limited
      Usage: Risedronate sodium is indicated for the treatment and prevention of postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis, and Paget's disease. It helps reduce the incidence of fractures and increases bone mass. Regular re-evaluation is recommended for ongoing treatment necessity.
    • zoledronic acid

      (Zoledronic Acid)
      Mylan Institutional LLC
      Usage: Zoledronic acid injection is indicated for the treatment of Paget's disease of bone in adults. It is recommended for patients with elevated serum alkaline phosphatase, those who are symptomatic, or those at risk for complications from the disease.